Omics and Artificial Intelligence in Kidney Diseases.

Artificial Intelligence Computational Machine learning Modeling Prediction Stratification

Journal

Advances in kidney disease and health
ISSN: 2949-8139
Titre abrégé: Adv Kidney Dis Health
Pays: United States
ID NLM: 9918523075306676

Informations de publication

Date de publication:
01 2023
Historique:
received: 06 10 2022
revised: 28 10 2022
accepted: 16 11 2022
entrez: 1 2 2023
pubmed: 2 2 2023
medline: 4 2 2023
Statut: ppublish

Résumé

Omics applications in nephrology may have relevance in the future to improve clinical care of kidney disease patients. In a short term, patients will benefit from specific measurement and computational analyses around biomarkers identified at various omics-levels. In mid term and long term, these approaches will need to be integrated into a holistic representation of the kidney and all its influencing factors for individualized patient care. Research demonstrates robust data to justify the application of omics for better understanding, risk stratification, and individualized treatment of kidney disease patients. Despite these advances in the research setting, there is still a lack of evidence showing the combination of omics technologies with artificial intelligence and its application in clinical diagnostics and care of patients with kidney disease.

Identifiants

pubmed: 36723282
pii: S2949-8139(22)00006-4
doi: 10.1053/j.akdh.2022.11.005
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-52

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Nadja Grobe (N)

Renal Research Institute, New York, NY. Electronic address: nadja.grobe@rriny.com.

Josef Scheiber (J)

BioVariance GmbH, Waldsassen, Germany.

Hanjie Zhang (H)

Renal Research Institute, New York, NY.

Christian Garbe (C)

Frankfurter Innovationszentrum Biotechnologie, Frankfurt am Main, Germany.

Xiaoling Wang (X)

Renal Research Institute, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH